Dechra Pharmaceuticals Stock

DPH

GB0009633180

Delayed London S.E. 02:30:00 2024-01-16 EST			5-day change	1st Jan Change
3,866.00 ^GBX	-.--%		-.--%	-

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI

Valuation: Dechra Pharmaceuticals

Market Cap	4.4B 5.99B 5.14B 4.8B 8.28B 573B 8.42B 56.64B 22.18B 287B 22.5B 22.01B 950B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.58B 5.64B 5.27B 9.09B 629B 9.24B 62.17B 24.34B 315B 24.7B 24.16B 1,043B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : Dechra Pharmaceuticals

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-30	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
25-10-13	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
25-10-13	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
25-09-02	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
25-08-18	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
25-06-16	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
25-05-05	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
25-05-05	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
24-07-17	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals

23-06-27	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
23-06-27	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
23-06-27	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
23-03-07	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
23-01-12	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals

23-12-27	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
23-10-30	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
23-09-06	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals

24-01-12	BOLETÍN MATINAL : 12 de enero de 2024
23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	2024-06-09
Paul Sandland DFI	Director of Finance/CFO	46	2019-04-02
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	2019-10-29
Lawson Macartney BRD	Director/Board Member	68	2016-11-30
Lisa Bright BRD	Director/Board Member	59	2019-01-31

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

3 years	3,680	3,868
5 years	2,473.32	5,525
10 years	1,225	5,525

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/15/24	Ian Page	Free	Chief Executive Officer	18,551	0.0163%
1/15/24	Paul Sandland	Free	Chief Financial Officer	2,293	0.0020%
1/15/24	Ian Page	Buy	Chief Executive Officer	627	0.0006%

	2022	2023
Net sales	682M 928M 796M 743M 1.28B 88.68B 1.3B 8.77B 3.43B 44.47B 3.48B 3.41B 147B	762M 1.04B 889M 830M 1.43B 99.04B 1.46B 9.79B 3.84B 49.67B 3.89B 3.81B 164B
Net income	58.2M 79.2M 67.93M 63.43M 109M 7.57B 111M 749M 293M 3.8B 297M 291M 12.55B	-27.9M -37.96M -32.57M -30.41M -52.47M -3.63B -53.33M -359M -141M -1.82B -143M -139M -6.02B
Net Debt	208M 283M 243M 227M 392M 27.08B 398M 2.68B 1.05B 13.58B 1.06B 1.04B 44.9B	430M 585M 502M 469M 809M 55.94B 822M 5.53B 2.17B 28.06B 2.2B 2.15B 92.76B

Dechra Pharmaceuticals Stock

Stocks

DPH

GB0009633180

Valuation: Dechra Pharmaceuticals

Latest news : Dechra Pharmaceuticals

Analysts' recommendations: Dechra Pharmaceuticals

Press Releases: Dechra Pharmaceuticals

News in other languages: Dechra Pharmaceuticals

Course Extremes

Managers and Directors: Dechra Pharmaceuticals

Latest insider transactions

Financials

Company Profile